Financial news scored by AI. No noise, no delay. Latest: FDA Approves AstraZeneca's Imfinzi for Muscle-Invasive Bladder Cancer (Impact: +90). OpenBell scores breaking market news for potential price impact, so you can see why it matters, not just that it happened.

Financial News with AI Impact Scores

Get real-time financial news with AI-powered impact analysis delivered through Discord

Today's Market Overview

openbell provides real-time news intelligence for smarter trades. Latest stories cover Healthcare, Unknown sectors. Top story: "FDA Approves AstraZeneca's Imfinzi for Muscle-Invasive Bladder Cancer" with +90 impact score. Join our Discord community for real-time alerts and discussions.

Latest News

Healthcare +90 AZN Nov 14, 09:01 PM

FDA Approves AstraZeneca's Imfinzi for Muscle-Invasive Bladder Cancer

The FDA approved AstraZeneca’s Imfinzi (durvalumab) with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi alone after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval adds a treatment option for this patient group; the article reports no financial figures or stock-price impact.

Unknown +65 MRL Nov 14, 08:02 PM

Merlin Properties Raises 2026 FFO Guidance and Updates Data Center Strategy

Merlin Properties raised its 2026 funds from operations (FFO) guidance to EUR 0.58 per share. The company also updated its strategy for its 704 MW data center portfolio; the report did not provide further details on the changes or any stock-price impact.

Load More News